Mesa Laboratories, Inc. (MLAB)

Revenue by Segment

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Sterilization and Disinfection Control	101.57M	93.42M	75.12M	64.61M	59.04M
Sterilization and Disinfection Control Growth	8.72%	24.35%	16.27%	9.43%	11.15%
Biopharmaceutical Development	48.63M	48.73M	40.71M	47.37M	45.58M
Biopharmaceutical Development Growth	-0.21%	19.69%	-14.05%	3.92%	34.48%
Calibration Solutions	53.55M	51.75M	47.76M	44.81M	46.87M
Calibration Solutions Growth	3.48%	8.35%	6.60%	-4.41%	-0.12%
Clinical Genomics	45.39M	47.08M	52.59M	62.30M	32.84M
Clinical Genomics Growth	-3.60%	-10.47%	-15.59%	89.70%	-
Total	249.13M	240.98M	216.19M	219.08M	184.34M
Total Growth	3.38%	11.47%	-1.32%	18.85%	37.63%

Revenue by Geography

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
United States	116.62M	106.40M	117.28M	99.07M
United States Growth	9.61%	-9.28%	18.38%	38.78%
China	25.31M	24.93M	25.80M	16.52M
China Growth	1.52%	-3.35%	56.18%	149.82%
Other	99.05M	84.86M	76.00M	68.75M
Other Growth	16.72%	11.65%	10.55%	22.90%
Total	240.98M	216.19M	219.08M	184.34M
Total Growth	11.47%	-1.32%	18.85%	37.63%

Source: S&P Global Market Intelligence.